Lorlatinib
Category: CancerLorlatinib Overview
Lorlatinib, sold under the brand name Lorbrena in the United States, Canada, and Japan, and Lorviqua in the European Union, is an anti-cancer drug developed by Pfizer. It is an orally administered inhibitor of ALK and ROS1, two enzymes that play a role in the development of cancer.[1] Contents 1 Medical uses 2 Contraindications 3 Side effects 4 Interactions 5 Pharmacology 5.1 Mechanism of action 5.2 Pharmacokinetics 6 Chemistry 7 History 7.1 Clinical studies 7.2 Approval...
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Lorlatinib
Recent Lorlatinib Forums:
Be the first to start a discussion about this drug.Possible Dosages for this and Related Drugs:
Lorlatinib
- Tablet: 100mg, 25mg
Other drugs which contain Lorlatinib or a similar ingredient: (1 result)
- LORBRENA Lorlatinib